| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 766,208 | 874,565 | 776,133 | NaN |
| Cost of sales | 194,999 | 275,709 | 140,085 | NaN |
| R&d expenses-Research And Early Pipeline | 87,291 | 103,547 | 93,720 | NaN |
| R&d expenses-Later Stage Clinical Programs | 36,177 | 29,260 | 251,650 | NaN |
| R&d expenses-Marketed Products | 55,328 | 59,606 | 64,108 | NaN |
| S&m expenses | 124,927 | 174,198 | 131,327 | NaN |
| G&a expenses | 133,363 | 272,009 | 137,088 | NaN |
| Other segment expense, net | 28,596 | 6,809 | -11,101 | NaN |
| Net income | 105,527 | -46,573 | -30,744 | 240,532 |
| Depreciation and amortization | 16,411 | 20,438 | 18,487 | 18,563 |
| Non-cash interest expense | 6,086 | 653 | 649 | 660 |
| Accretion of discount on investments | 455 | 1,106 | 978 | 1,355 |
| Stock-based compensation | 43,458 | 46,913 | 49,265 | 47,531 |
| Gain on sale of nonfinancial assets | NaN | 0 | 0 | 0 |
| Impairment of assets | 0 | 122,045 | 0 | 0 |
| Acquired in-process research & development expense | NaN | 0 | 220,963 | NaN |
| Roctavian inventory write-off | NaN | 119,208 | NaN | NaN |
| Deferred income taxes | 9,220 | 613 | -13,646 | 33,342 |
| Unrealized foreign exchange losses (gains) | -6,710 | -4,215 | -5,550 | -4,720 |
| Other | 5,374 | 2,710 | -212 | 649 |
| Accounts receivable, net | 7,159 | 120,676 | -48,746 | 98,534 |
| Inventory | -44,490 | 18,133 | 26,334 | 48,127 |
| Other current assets | 11,551 | -41,016 | 17,033 | 8,765 |
| Other assets | -1,484 | 5,894 | 19,174 | 11,881 |
| Accounts payable and accrued liabilities | 3,100 | -53,342 | 116,367 | 5,766 |
| Other long-term liabilities | 8,704 | -7,023 | 16,355 | 3,468 |
| Net cash provided by operating activities | 220,651 | 99,644 | 368,685 | 185,271 |
| Purchases of property, plant and equipment | 20,923 | 40,722 | 28,447 | 17,101 |
| Maturities and sales of investments | 767,277 | 43,254 | 98,809 | 117,934 |
| Purchases of investments | 25,792 | 42,613 | 110,829 | 113,159 |
| Proceeds from sale of nonfinancial assets | NaN | 0 | 0 | 0 |
| Purchase of intangible assets | NaN | 2,368 | 5,303 | 266 |
| Acquisition, net of cash acquired | NaN | 0 | 285,193 | NaN |
| Other | -4,966 | 0 | 0 | NaN |
| Net cash provided by (used in) investing activities | 725,528 | -42,449 | -330,963 | -12,592 |
| Repayments of convertible debt | NaN | 0 | 0 | NaN |
| Other | NaN | -889 | 0 | 0 |
| Proceeds from exercises of awards under equity incentive plans | NaN | 6,746 | 7 | 7,707 |
| Taxes paid related to net share settlement of equity awards | 28,180 | 2,700 | 2,176 | 12,310 |
| Proceeds from issuance of debt | 850,000 | NaN | NaN | NaN |
| Payments of debt issuance costs | 8,653 | NaN | NaN | NaN |
| Net cash provided by (used in) financing activities | 813,167 | 3,157 | -2,169 | -4,603 |
| Effect of exchange rate changes on cash | 1,410 | 1,219 | 739 | -3,063 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 1,760,756 | 61,571 | 36,292 | 165,013 |
| Beginning of period | 1,311,679 | -307,266 | 942,842 | NaN |
| End of period | 3,072,435 | 61,571 | 1,250,108 | NaN |
BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN)